TREM2: Keeping Pace With Immune Checkpoint Inhibitors in Cancer Immunotherapy

To date, immune checkpoint inhibitors have been successively approved and widely used in clinical cancer treatments, however, the overall response rates are very low and almost all cancer patients eventually progressed to drug resistance, this is mainly due to the intricate tumor microenvironment an...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Hui, Shao, Zhiying, Wen, Xin, Jiang, Jinghua, Ma, Qinggong, Wang, Yan, Huang, Long, Ding, Xin, Zhang, Longzhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446424/
https://www.ncbi.nlm.nih.gov/pubmed/34539652
http://dx.doi.org/10.3389/fimmu.2021.716710

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446424/
https://www.ncbi.nlm.nih.gov/pubmed/34539652
http://dx.doi.org/10.3389/fimmu.2021.716710

Ejemplares similares